Phoenix Kineticream Anti-inflammatory And Pain Relief

Menthol


Pure Source, Llc
Human Otc Drug
NDC 65121-032
Phoenix Kineticream Anti-inflammatory And Pain Relief also known as Menthol is a human otc drug labeled by 'Pure Source, Llc'. National Drug Code (NDC) number for Phoenix Kineticream Anti-inflammatory And Pain Relief is 65121-032. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Phoenix Kineticream Anti-inflammatory And Pain Relief drug includes Menthol - 20 mg/mL . The currest status of Phoenix Kineticream Anti-inflammatory And Pain Relief drug is Active.

Drug Information:

Drug NDC: 65121-032
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Phoenix Kineticream Anti-inflammatory And Pain Relief
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Menthol
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Pure Source, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:MENTHOL - 20 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 22 May, 2013
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Pure Source, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1102253
1424356
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:L7T10EIP3A
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
65121-032-04118 mL in 1 TUBE (65121-032-04)07 Feb, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose topical pain relief

Product Elements:

Phoenix kineticream anti-inflammatory and pain relief menthol aloe vera leaf water arnica montana bromelains shea butter c13-14 isoparaffin green tea leaf cetostearyl alcohol citric acid monohydrate bergamot oil dimethyl sulfone emu oil ethylhexylglycerin glucosamine sulfate glycerin glyceryl stearate se laureth-7 peppermint oil papain phenoxyethanol polysorbate 20 willow bark sesame oil stearic acid cocoa butter .alpha.-tocopherol xanthan gum menthol menthol

Indications and Usage:

Uses temporary relieves of these symptoms: minor aches pains associated with simple backache arthritis bruises sprains cramps muscle strains.

Warnings:

Warnings for external use only. use only as directed children under 6 years, ask a doctor. stop use and ask a doctor if: condition worsen pain persist of more than 7 days irritation develops avoid contact with eyes and open wounds. if swallowed, get medical help or contact your local poison control center or emergency room immediately. if pregnant or breast feeding ask a health professional before use. keep out of reach of children.

Dosage and Administration:

Directions adults and children 6 years and over: before activity, massage onto muscles and joints until absorbed into skin. after activity, apply generously to tired and affected areas apply to dry and cleans areas repeat as needed, up to 6 times daily.

Stop Use:

Stop use and ask a doctor if: condition worsen pain persist of more than 7 days irritation develops avoid contact with eyes and open wounds. if swallowed, get medical help or contact your local poison control center or emergency room immediately.

Package Label Principal Display Panel:

Package labeling: tube


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.